Pharmacological Management of Osteoporosis in Post-Menopausal Women: An Endocrine Society Clinical Practice Guideline
Clifford J Rosen, MD
Maine Medical Center Research Institute, Scarborough, ME
Dr. Clifford Rosen is the Principal Investigator for the Rosen Musculoskeletal Laboratory at the Maine Medical Center Research Institute (MMCRI) and is board certified endocrinologist. Dr. Rosen has more than twenty-five years of continuous NIH funding, first at The Jackson Laboratory and subsequently at MMCRI. In 2007 Dr. Rosen moved from The Jackson Laboratory to MMCRI where he was appointed senior scientist and director of clinical and translational research. In the last ten years the Rosen laboratory has been studying mesenchymal stem cell fate with particular reference to the switch between pre-adipocytes and pre-osteoblasts, and with a focus on the bioenergetic programs of those progenitors. There are currently four NIH funded projects in this laboratory, focused on a central theme of lineage allocation, its biochemical determinants and its alterations in osteoporosis. An R24 program project on the biology of marrow adiposity is now finishing in its 6th year at NIDDK and Dr. Rosen is the contact PI for that four center interdisciplinary program. There are three other NIH funded research projects for which Dr. Rosen serves as the PI: An R01 from NIDDK in collaboration with Roland Baron at Harvard Medical Dental School that examines the role of the PTH1R in cell fate, an RO1 from NIAMS studying mechanical strength in outbred strains of mice and an R21(NIAMS) to delineate the impact of anabolic therapy on marrow adipogenesis. Dr. Rosen is also the Director of the Physiology Core of the MMCRI Stem Cell COBRE and the newly funded COBRE in Mesenchymal and Neural Regulation of Metabolic Networks (NIGMS); he oversees whole body and cell phenotyping related to metabolic function in mice. The Rosen laboratory has also been interested in mitochondrial function in osteoblasts with an R21 on control of osteogenic bioenergetics that was recently completed. He also serves as the Principal Investigator for a NIGMS sponsored U54: The Northern New England Clinical and Translational Research Network. Dr. Rosen is the past president of the American Society of Bone and Mineral Research and is a council member for the Endocrine Society. He is currently an Associate Editor at New England Journal of Medicine, Endocrine Reviews and a Board of Reviewing Editor at eLife. Dr. Rosen has published 483 peer-reviewed publications in Journals such as Nature, Nature Medicine, Cell, Cell Metabolism, PNAS, New England Journal and Lancet. Dr. Rosen is a member of the NIA (NACA) Council serving a 4 year term.
Nelson B Watts, MD
Mercy Health, Cincinnati, OH
Nelson B. Watts, MD, FACP, MACE, CCD, currently serves as Director of Osteoporosis and Bone Health Services for Mercy Health, an integrated health system in Cincinnati, Ohio. He has a long career in osteoporosis research at Emory University and the University of Cincinnati. He has served as President of the American College of Endocrinology, President of the International Society of Clinical Densitometry, Chair of the FDA's Advisory Committee for Endocrine and Metabolic Drugs and on the ABIM subspecialty board in Endocrinology and Metabolism. He is active in numerous professional organizations and serves on several editorial boards. He has published numerous, books, book chapters, abstracts and articles in such journals as the New England Journal of Medicine and the Journal of the American Medical Association.
Dolores M Shoback, MD
UCSF/VA Med Ctr, San Francisco, CA
Dr. Dolores Shoback is Professor of Medicine and Associate Program Director of the Fellowship Program in Diabetes, Endocrinology and Metabolism at the University of California, San Francisco School of Medicine. She attended the University of Pennsylvania (BA, Biology) and obtained her MD from Johns Hopkins University School of Medicine. She completed Internal Medicine residency at Johns Hopkins Hospital and her fellowship in Endocrinology and Hypertension at the Brigham and Women's Hospital/Harvard Medical School where she developed career-long interests in endocrine hypertension, metabolic bone disease, osteoporosis, and parathyroid disorders. In 1983, she joined the Endocrine Research Unit at the San Francisco Department of Veterans Affairs Medical Center and the University of California, San Francisco and joined the faculty in endocrinology in 1985. Dr. Shoback is active in basic and clinical research involving calcium-sensing receptors and parathyroid disorders. She has authored more than 150 research papers, reviews and chapters. Dr. Shoback served as Associate Editor for the Journal of Clinical Endocrinology and Metabolism and co-edited the last 3 editions of the Greenspan Textbook of Endocrinology and Metabolism. She has been honored as a Master Clinician in the UCSF Department of Medicine (2014), with membership in the UCSF Gold-Headed Cane Society (2015), the UCSF Class of 2015 Teaching Award for Clinical Faculty, the Sidney Ingbar Award for Distinguished Service of the Endocrine Society (2016), and the Parathyroid Medal from Fondazione Raffaella Becaglia in Florence (2017). She chaired the Endocrine Society's 2009 Annual Meeting and is currently Secretary-Treasurer elect of the Endocrine Society (2018-2022). Her research interests involve the application of therapeutics targeting the calcium-sensing receptor to bone and parathyroid diseases and novel combination therapies for osteoporosis in women and men based on new insights gleaned from basic science studies in mouse models.
Richard Eastell, MBChB, MD
University of Sheffield, Sheffield, United Kingdom
Richard Eastell BSc (Hons), MBChB, MD (Edin), FRCP (London, Edin), FRCPI (Hon), FRCPath, FMedSci, Professor of Bone Metabolism and Director of the Mellanby Centre for Bone Research at the University of Sheffield. Richard qualified in medicine from Edinburgh in 1977. He trained in endocrinology in Edinburgh, Northwick Park and at the Mayo Clinic (Dr B L Riggs). He leads a research group on the pathogenesis, diagnosis and treatment of osteoporosis; of particular note is his contribution to the use of bone turnover markers and the development of treatments for osteoporosis. His work has recently been recognised by the Ian MacIntyre Medal (2011), Philippe Bordier Award (2012) (European Calcified Tissue Society), Frederic C Bartter Award 2014 (American Society for Bone and Mineral Research), Faculty Member of ASBMR (2018) and Kohn Award (2004) and Linda Edwards Award from the National Osteoporosis Society (2018).